Gok Ozlem, Karaali Zeynep, Ergen Arzu, Ekmekci Sema Sirma, Abaci Neslihan
Department of Genetics, Aziz Sancar Institute of Experimental Medicine (Aziz Sancar DETAE), Istanbul University, Istanbul, Turkey.
Department of Internal Medicine, Haseki Training and Research Hospital, Istanbul, Turkey.
J Res Med Sci. 2019 Jun 25;24:56. doi: 10.4103/jrms.JRMS_921_18. eCollection 2019.
Type 2 diabetes (T2DM) is characterized by hyperglycemia and insulin deficiency. Sirtuin 1 (SIRT1), serving as a deacetylase, is critical in the regulation of glucose and lipid metabolism. Recently, a number of studies have been conducted to investigate the role of SIRT1 in the pathogenesis of T2DM. However, there are no sufficient data about the relationship between SIRT1 and T2DM. The aim of this study was to analyze the expressions of microRNAs (miRNAs) (miR-34a, miR-9, miR-132, and miR-181a) involved in SIRT1 regulation and SIRT1 protein in the serum of T2DM patients and controls.
miRNA expressions were determined by real-time polymerase chain reaction, and enzyme-linked immunosorbent assay was used to measure the SIRT1 protein levels in 25 T2DM patients and 25 controls.
Fasting blood glucose and glycated hemoglobin levels were significantly higher in patients when compared with controls ( < 0.001). There was no difference for miRNA expressions between the groups ( > 0.05). SIRT1 protein level was significantly increased in patients as compared to controls ( = 0.044). Moreover, SIRT1 was negatively correlated with miR-181a ( = -0.558, = 0.005) and miR-132 ( = -0.435, = 0.034) in patients.
Obtained results indicate that serum SIRT1 may be a potentially new biomarker for T2DM and also miR-181a and miR-132 may be involved in the development of T2DM by targeting SIRT1. This is the first study reporting on the effects of SIRT1 and related miRNAs in Turkish T2DM patients.
2型糖尿病（T2DM）的特征是高血糖和胰岛素缺乏。沉默调节蛋白1（SIRT1）作为一种去乙酰化酶，在葡萄糖和脂质代谢的调节中起关键作用。最近，已经进行了多项研究来探讨SIRT1在T2DM发病机制中的作用。然而，关于SIRT1与T2DM之间关系的数据并不充分。本研究的目的是分析参与SIRT1调节的微小RNA（miRNA）（miR-34a、miR-9、miR-132和miR-181a）以及T2DM患者和对照组血清中SIRT1蛋白的表达。
通过实时聚合酶链反应测定miRNA表达，并采用酶联免疫吸附测定法测量25例T2DM患者和25例对照组的SIRT1蛋白水平。
与对照组相比，患者的空腹血糖和糖化血红蛋白水平显著更高（<0.001）。两组之间的miRNA表达无差异（>0.05）。与对照组相比，患者的SIRT1蛋白水平显著升高（=0.044）。此外，在患者中，SIRT1与miR-181a（=-0.558，=0.005）和miR-132（=-0.435，=0.034）呈负相关。
所得结果表明，血清SIRT1可能是T2DM的一种潜在新生物标志物，并且miR-181a和miR-132也可能通过靶向SIRT1参与T2DM的发生发展。这是第一项报道SIRT1和相关miRNA对土耳其T2DM患者影响的研究。
